Given the centrality of B cells to systemic lupus erythematosus (SLE), it stands to reason that
a candidate therapeutic agent that targets B cells could be efficacious. Both rituximab, a …

Th17 cells are a distinct lineage of T-cells. These T-cells express IL-17A and the lineage-
defining transcription factor RORγt. Th17 cells have a pivotal, physiological role in host …

Objective B cells are likely to contribute to the pathogenesis of systemic lupus
erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III …

Dihydroxyvitamin D 3 (1, 25 (OH) 2 D 3) can modulate immune responses, but whether it
directly affects B cell function is unknown. Patients with systemic lupus erythematosus …

Mouse gene–targeting studies have documented a central role of the p110δ isoform of
phosphoinositide 3-kinase (PI3K) in B-cell development and function. A defect in B-cell …

Objective To determine the phenotype and the functionality of natural killer (NK) cells in
patients with systemic lupus erythematosus (SLE). Methods A total of 94 patients with SLE …

The EXPLORER study was designed to assess the response to rituximab versus placebo in
patients with moderate to severe extrarenal systemic lupus erythematosus (SLE) receiving …

B lymphocytes from patients with systemic lupus erythematosus (SLE) are characterized by
reduced expression levels of membrane CD5. Recent studies from our laboratory have …

Lupus nephritis (LN) is one of the most serious complications of systemic lupus
erythematosus (SLE) since it is the major predictor of poor prognosis. In susceptible …

Lupus nephritis (LN) is a common and severe organ manifestation of systemic lupus
erythematosus (SLE), and is associated with significant patient morbidity and mortality …